Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernAlum-CpG의 수용체 결합 도메인 재조합 단백질은 우려되는 SARS-CoV-2 변이체에 대한 광범위한 보호를 유도합니다Article Published on 2022-06-092022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] (Alpha) (Beta) addition adjuvant Alpha alum aluminum aluminum hydroxide Antibody titer Antibody titers B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 benefit Beta Cellular immune response conducted Controller convalescent plasma Corbevax COVID-19 CpG Delta dose drug Emergency use authorization evaluated exceeded hydroxide immune response immunized induce Infection intramuscularly mice neutralization Neutralizing antibodies neutralizing antibody neutralizing antibody titers omicron other variants preclinical studies preclinical study Protein Receptor-binding domain reported SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 variant second dose subunit Subunit vaccine TLR9 TLR9 adjuvant Vaccine vaccine candidate variant variants variants of concern Virus neutralization Wuhan Wuhan isolate yeast [DOI] 10.1016/j.vaccine.2022.05.007 PMC 바로가기 [Article Type] Article
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRandomized Controlled Trial Published on 2022-06-092022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, 진단, [키워드] 95% CI addition Adjusted analysis anti-SARS-CoV-2 anti-Spike IgG Antibody Response assigned AstraZeneca baseline benefit BNT162b2 booster Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Cohort COVID-19 vaccine dose Effect eight EudraCT Evidence Exploratory analyses Exploratory analysis finding funding Future geometric mean concentration geometric mean ratio group groups Heterologous heterologous vaccine homologous humoral humoral immunogenicity immune persistence immune response immunogenic immunogenicity analysis Immunological response intention-to-treat interval intervals ISRCTN ITT ITT analysis less Older participant persistence Pfizer/BioNTech platform priming randomised Randomly reactogenic reactogenicity reduced Registered SARS-COV-2 infection second dose significant difference significantly higher spike IgG study groups Support T-cell Response the vaccine titre Trial Vaccine Virus neutralisation [DOI] 10.1016/S2213-2600(22)00163-1 [Article Type] Randomized Controlled Trial
Immunological characteristics of MAV/06 strain of varicella-zoster virus vaccine in an animal modelArticle Published on 2022-06-032023-05-31 Journal: BMC Immunology [Category] 두창, 수두, 홍역, [키워드] Cellular immune response MAV/06 vaccine Serological cross-reactivity Varicella zoster virus [DOI] 10.1186/s12865-022-00503-6 PMC 바로가기
Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysisData article Published on 2022-06-012022-10-05 Journal: Sensors (Basel, Switzerland) [Category] 변종, [키워드] acute respiratory syndrome assays cellular Cellular immune response Complete coronavirus coronavirus disease COVID-19 COVID-19 vaccination dialysis dose Effectiveness ELISPOT exclusion General population Hemodialysis homologous humoral immune response immune response Immunity immunoassay immunoglobulins increased risk interferon-γ Microparticle morbidity and mortality Patient Peritoneal dialysis produced reactogenicity receiving regimen SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine single dose T cells tested the vaccine trials vaccination [DOI] 10.1016/j.dib.2022.108271 [Article Type] Data article
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational StudyOcrelizumab 및 기타 질병 수정 요법을 사용하는 다발성 경화증 환자의 SARS-CoV-2 감염에 대한 세포 및 체액 면역: 다민족 관찰 연구Observational Study Published on 2022-06-012022-09-11 Journal: Annals of neurology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] age ANN antibody Antibody Response Antibody responses assays association Asymptomatic cellular Cellular and humoral immunity Cellular and humoral responses Cellular immune response chemiluminescence immunoassay Clinical course Clinical severity coronavirus disease Coronavirus disease 2019 correlated correlation COVID-19 determine domain Effect ELISA ELISPOT ELISpot assays enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence evidence of group Hospitalized humoral Humoral and cellular immune responses Humoral immunity Humoral response humoral responses IFNγ IL-2 immune responses immunoassay immunologic response immunologic responses Infection Laboratory Live virus microneutralization MOST Multiple multiple sclerosis multivariate analyses Multivariate analysis N-terminal domain Natalizumab not differ Ocrelizumab Other Patient performed Protein RBD receptor recruited respiratory response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike sclerosis Severe acute respiratory syndrome severity Spearman sphingosine spike Spike protein symptomatic infection T-cell Response T-cell responses therapy with COVID-19 [DOI] 10.1002/ana.26346 PMC 바로가기 [Article Type] Observational Study
ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccinationChAdOx1-S 아데노바이러스 벡터백신을 비강내 투여하여 근육주사에 비해 점막면역력이 우수함Article Published on 2022-06-012022-09-12 Journal: European Journal of Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] adenoviral vector adenoviral vector vaccine Administered Antibody titer applied approved BALB/c mice breakthrough infections CD8 T cell Cellular immune response ChAdOx1-S Complete COVID-19 COVID-19 pandemic elicit elicited exhibiting expressing form full-length humoral IgA IgG antibody Immunity immunization immunized immunized mice induce intramuscular intramuscular vaccination intramuscularly intranasal intranasally lung mice mucosa mucosal mucosal immunity neutralized neutralizing capacity percentage phenotype Prevent Protein robust SARS-CoV-2 sera spike the disease the Spike tissue vaccination Vaccine vaccine vectors. vectors virus entry [DOI] 10.1002/eji.202249823 PMC 바로가기 [Article Type] Article
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity선천성 면역이상이 있는 성인 환자에서 mRNA-1273 코로나19 백신의 면역원성Controlled Clinical Trial Published on 2022-06-012022-09-12 Journal: The Journal of Allergy and Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome All participant antibodies antibody Antibody Response Antibody titer baseline binding Cellular immune response CID clinically cohorts comparable Complication complications Control coronavirus correlated COVID-19 COVID-19 vaccination COVID-19 vaccine CVID deficiencies deficiency dose first vaccination healthy controls humoral immune response Immunity immunodeficiency immunogenic immunogenicity immunosuppressive drug Inborn error inborn errors of immunity increased risk Level Mild mRNA-1273 mRNA-1273 COVID-19 vaccine multicenter Neutralizing antibodies Patient patient group patients patients with CVID phagocyte Primary immunodeficiency disorders SARS-CoV-2 second vaccination seroconversion rate T-cell T-cell Response the antibody response vaccination against COVID-19 Vaccinations were assessed X-linked agammaglobulinemia XLA [DOI] 10.1016/j.jaci.2022.04.002 PMC 바로가기 [Article Type] Controlled Clinical Trial
Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis항-CD20 치료 다발성 경화증에서 SARS-CoV-2에 대한 보존된 T 세포 반응Article Published on 2022-06-012022-09-11 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-CD20 anti-CD20 therapy anti-SARS-CoV-2 anti-SARS-CoV-2 spike protein antibodies Antibody avidity avidity CD20 Cellular immune response Cohort Coronavirus-2 detectable healthy control healthy controls humoral Humoral and cellular immune responses IgA IgG IgG level IgG levels immune responses Immunoglobulin Immunoglobulin G infected with SARS-CoV-2 management Multiple multiple sclerosis neutralizing capacity occurred pandemic Patient respiratory SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 spike protein SARS-CoV-2 vaccination SARS-CoV-2-specific T cell SARS-CoV-2-specific T cells second vaccination Spike protein T cell response T cells treated Treatment vaccination Vaccinations virus were measured [DOI] 10.1177/13524585221094478 PMC 바로가기 [Article Type] Article
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough InfectionsSARS-CoV-2-나이브 및 -경험 대상자에서 BNT162b2 mRNA 백신에 대한 세포 및 체액 면역 반응의 동역학 및 지속성: 추가 용량 및 돌발 감염의 영향Article Published on 2022-05-312022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] administration age analyzed Anti-nucleocapsid antibodies anti-SARS-CoV-2 anti-spike antibodies anti-spike antibody antibodies antibody association Belgium benefit blood sample Blood samples blood sampling BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine booster booster dose booster doses breakthrough infections cell-mediated immune response cellular cellular and humoral immune response Cellular immune response cellular immune responses collected COVID-19 COVID-19 vaccine DiaSorin dose Elecsy enrolled evaluated greater HCW HCWs Healthcare system healthcare worker Healthcare workers help Human humoral Humoral and cellular immune responses humoral immune response Humoral response IFN-γ IgG immune protection immune response immune responses immunization immunogenicity Impact implication increase in individual level individuals Infection initial Kinetics LIAISON Lymphocytes management mandatory mRNA vaccination mRNA vaccine naïve naïve individuals natural infection Neutralization assay neutralization capacity Neutralizing antibodies pandemic participant Participants Peripheral blood peripheral blood lymphocyte peripheral blood lymphocytes persistence Prevent Prospective Study Qiagen QuantiFERON quantified reduce regimen response SARS- CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination second dose secretion severe COVID-19 significantly higher tested the SARS-CoV-2 triggering understanding university vaccination vaccine dose variant Vero E6 was performed [DOI] 10.3389/fimmu.2022.863554 PMC 바로가기 [Article Type] Article
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review혈액암 환자를 위한 COVID-19 백신의 효과, 면역원성 및 안전성: 체계적인 검토Article Published on 2022-05-312022-09-12 Journal: Blood Cancer Journal [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] adverse event appear approach approved B-cell cellular Cellular immune response Chemotherapy Clinical efficacy Clinical outcome conducted COVID-19 COVID-19 vaccination COVID-19 vaccine database death depleting disease dose Efficacy eligible hematological Hematological malignancy highest HM patient Hospital admission humoral immune impairment individual leukemia lowest pandemic parameters Patient patient population patients Prospective Study ranged regimens reported respond SARS-COV-2 infection SARS-CoV-2 vaccination serious AE seroconversion rate Severe infection symptomatic disease systematic review T-cell Response Treatment Vaccines [DOI] 10.1038/s41408-022-00684-8 PMC 바로가기 [Article Type] Article